Doximity, Inc. (NASDAQ:DOCS – Get Free Report) Director Timothy S. Cabral sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the transaction, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Doximity Stock Up 35.5 %
Doximity stock opened at $78.97 on Friday. Doximity, Inc. has a 52 week low of $22.96 and a 52 week high of $80.71. The company’s 50 day moving average price is $55.61 and its two-hundred day moving average price is $45.66. The stock has a market cap of $14.74 billion, a P/E ratio of 90.77, a P/E/G ratio of 4.68 and a beta of 1.39.
Doximity (NASDAQ:DOCS – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02). The business had revenue of $136.83 million for the quarter, compared to the consensus estimate of $127.05 million. Doximity had a return on equity of 19.79% and a net margin of 33.69%. During the same quarter last year, the business posted $0.18 earnings per share. On average, equities analysts anticipate that Doximity, Inc. will post 0.88 EPS for the current year.
Institutional Investors Weigh In On Doximity
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on DOCS shares. Mizuho began coverage on shares of Doximity in a research report on Wednesday, December 4th. They set a “neutral” rating and a $55.00 target price on the stock. Bank of America increased their price objective on shares of Doximity from $54.00 to $57.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. The Goldman Sachs Group began coverage on Doximity in a research report on Friday, November 15th. They issued a “neutral” rating and a $58.00 target price for the company. Piper Sandler upgraded Doximity from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $31.00 to $78.00 in a report on Friday. Finally, Barclays boosted their price objective on Doximity from $52.00 to $75.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Twelve equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Doximity currently has a consensus rating of “Hold” and a consensus price target of $62.44.
Check Out Our Latest Stock Analysis on DOCS
About Doximity
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Further Reading
- Five stocks we like better than Doximity
- The How And Why of Investing in Oil Stocks
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.